We show that Sema3A mRNA is expressed in lymphatic vessels and that Sema3A protein binds to lymphatic valves expressing the Neuropilin-1 (Nrp1) and PlexinA1 receptors. Using mouse knockout models, we show that Sema3A is selectively required for lymphatic valve formation, via interaction with Nrp1 and PlexinA1. Sema3a ؊/؊ mice exhibit defects in lymphatic valve formation, which are not due to abnormal lymphatic patterning or sprouting, and mice carrying a mutation in the Sema3A binding site of Nrp1, or deficient for Plxna1, develop lymphatic valve defects similar to those seen in Sema3a ؊/؊ mice. 
T he vertebrate circulatory system distributes oxygen, nutrients, and hormones to tissues and collects carbon dioxide and other metabolic waste products. Blood pressure causes plasma constituents to extravasate from the arterial side of the capillary bed into the interstitial space. The lymphatic system participates in the reabsorbance of this fluid and drains it back into the venous circulation. In healthy adult humans, the lymphatic system returns approximately 1 to 2 L of interstitial fluid with 20 to 30 g of protein per liter to the venous circulation every day. 1 The lymphatic network also plays a key role in immune responses by serving as a conduit for extravasated leukocytes and activated antigen-presenting cells. [2] [3] [4] Blind-ended lymphatic capillaries are functionally specialized to allow entry of fluid containing macromolecules and leukocytes, termed lymph. Lymphatic capillaries form a highly branched network that permeates all body tissues, with the exception of bone and the central nervous system. In the small intestine, lacteal lymphatic capillaries inside the intestinal villi absorb chylomicrons of dietary lipids released by intestinal epithelial cells. Collecting lymphatic vessels transport the lymph through a network of progressively larger conduits back into the venous circulation. 5 Structural differences between lymphatic capillaries and collecting vessels allow for efficient fluid uptake and transport, respectively. Capillaries exhibit button-like junctions that are anchored to filaments in the extracellular matrix (ECM), which exert tension to keep the junctions opened and allow fluid entry. In contrast, collecting lymphatic vessels have zipper-like junctions, which avoid fluid leakage. 6 Col-lecting lymphatics also develop valves, which prevent backflow of lymph. Defects in valve formation cause congenital lymphedema, a severe and progressive condition characterized by gross swelling of the extremities accompanied by fibrosis and susceptibility to infections. 7 Cellular and molecular mechanisms regulating lymphatic valve formation are only beginning to be understood. Valve formation in mice is initiated during late embryonic development by specification of valve forming cells, which are defined by high expression levels of the transcription factors Prox1 and Foxc2. 8 The same transcriptional program also regulates formation of venous valves 9 and is triggered by oscillatory shear stress in lymphatic valves, which often form at branch points of lymphatic vessels. 10 Foxc2 regulates positioning and specification of lymphatic valves within the collecting lymphatic vessels, and loss of Foxc2 leads to loss of luminal valves and abnormal lymph flow. 11 Mutations in human FOXC2 cause lymphedema-distichiasis. 12 After specification, lymphatic valve cells delaminate from the vessel wall, extend, and migrate into the lumen and mature into heart-shaped leaflets capable of preventing lymph backflow. 10 The elongation process requires Integrin-␣9 (Itg␣9) interactions with fibronectin-EIIIA in the ECM. 13 Whether guidance molecules participate to lymphatic valve formation has not been investigated yet.
Sema3A, a member of class 3 secreted semaphorins, is expressed in adult lymphatic vessels and regulates entry of dendritic cells into lymphatics via an interaction with PlexinA1 and Neuropilin-1 (Nrp1) receptors expressed in dendritic cells. 4 Expression of Sema3A in lymphatic vessels suggested that Sema3A might play a role in lymphatic vessel development. We therefore investigated Sema3A expression in lymphatics and vascular development in Sema3a Ϫ/Ϫ mice. We show that Sema3A is expressed in neonatal lymphatic vessels and selectively regulates lymphatic valve formation but not sprouting or assembly of lymphatic vessels.
Sema3A binds to Nrp1, but in some cell types it has been shown to signal via the Neuropilin-2 (Nrp2) receptor. 14 Previous results demonstrated that Nrp2 is the predominant neuropilin expressed in lymphatic vessels, whereas Nrp1 is expressed in embryonic arteries. [15] [16] [17] [18] [19] We observed that expression of the Nrp1 receptor is elevated in lymphatic valves and that Sema3A protein strongly binds to lymphatic valves. In contrast, Nrp2 expression is excluded from the lymphatic valve-forming area. In agreement with this expression pattern, Nrp2 mutants formed normal lymphatic valves, whereas mice lacking Sema3a or carrying a mutation in the Sema3A binding site of Nrp1 (Nrp1 semaϪ/Ϫ , 20 ) have small valves that were abnormally covered by smooth muscle cells (SMC). Furthermore, lymphatic valves express 1 of the 4 Plexin type A signal-transducing receptors, PlexinA1, and Plxna1 mutants also have similar lymphatic valve defects. These results reveal a previously unanticipated and selective role for Sema3A-Nrp1-PlexinA1 signaling in the lymphatic component of the vascular system.
Methods
An expanded Methods section is available in the Online Data Supplement.
Results
To investigate Sema3A function in lymphatic vessel development, we first confirmed Sema3A expression in developing lymphatic vessels using in situ hybridization. Whole-mount staining of mesenteries from newborn mice showed robust labeling of lymphatic vessels but not arteries or veins with a Sema3a antisense riboprobe ( Figure 1A ). Sense probes did not show any signal (data not shown). To localize binding sites for Sema3A protein, we incubated mesenteries with an alkaline-phosphatase (AP)-tagged Sema3A protein (Sema3A-AP). Sema3A-AP bound prominently to lymphatic valves ( Figure 1B) . In contrast, AP-tagged VEGF-A protein bound to arteries and veins but not to lymphatic vessels ( Figure 1C ). This observation raised the possibility that Sema3A bound to cognate receptors on lymphatic valves to regulate valve formation.
Sema3A is known to bind to Nrp1 but can, in some cell types, also signal via Nrp2. 14 In situ hybridization showed that Nrp1 mRNA was most prominently expressed in the lymphatic valve-forming areas ( Figure 1D ). Furthermore, lymphatic valve-forming areas expressed the Nrp1 coreceptor Plxna1 ( Figure 1E ) but none of the other A-type plexins (Online Figure I) . In contrast to Nrp1 and Plxna1, Nrp2 was expressed all along the mesenteric lymphatic vessels, but it appeared to be excluded from valve-forming areas ( Figure  1F ). 10 These observations suggested that lymphatic Sema3A might regulate valve formation through Nrp1-PlexinA1 signaling. In agreement with this hypothesis, Western blot analysis of cultured primary human dermal lymphatic endothelial cells (HDLEC) showed that these cells express Sema3A, Nrp1, and PlexinA1 protein ( Figure 1G ). Immunoprecipitation of HDLEC protein extracts with an anti-Nrp1 antibody pulled down PlexinA1 and Sema3A and pretreatment of HDLEC with Sema3A enhanced complex formation ( Figure 1H (Figure 2A through 2C), indicating that valves were properly specified in the absence of Sema3A. However, valve area was significantly smaller in Sema3a Ϫ/Ϫ mice when compared with wild-type littermates (Figure 2A , 2C, and 2E), suggesting that lack of Sema3A signaling impaired valve morphogenesis.
We next compared valve formation in mouse mutants deficient for Nrp1, Plxna1, or Nrp2. Because Nrp1 null mutants die during early embryonic development, 18, 21 we examined valve formation in mice carrying a deletion of the Sema3A binding site in the Nrp1 gene. 20 These mice show normal vascular development, indicating that semaphorin binding to Nrp1 is dispensable for vascular development. 20, 22 Strikingly, Nrp1 semaϪ/Ϫ mice formed abnormally small lymphatic valves similar to those seen in Sema3a Ϫ/Ϫ mice ( Figure 2D and 2E). Mice deficient in Plxna1 23 also developed smaller lymphatic valves ( Figure 2E and 2F). Quantification of the diameter of lymphatic, arterial, and venous vessels showed no significant differences between wild-type and mutant littermates (see Methods), indicating that Sema3A, Nrp1, and PlexinA1 are required in the vasculature for proper morphogenesis of the lymphatic valves. In contrast, mesenteric lymphatic vessels and valves were of normal appearance in Nrp2 knockout mice, and quantification of Itg␣9-positive valve area showed no difference between wild-type and Nrp2 Ϫ/Ϫ (Online Figure II) , ruling out Nrp2 as a Sema3A receptor on valves.
We next asked if Sema3A signaling was selectively required in the developing vasculature for lymphatic valve formation or if the absence of Sema3A might impair other aspects of vascular or lymphatic vessel development. 22, 24 To distinguish between these possibilities, we compared sprouting and assembly of lymphatic and blood vessels in wild-type and Sema3a Ϫ/Ϫ mice. High-magnification confocal analysis of lymphatic vessel sprouts showed a similar morphology in both genotypes and robust Nrp2 expression on sprouting tips ( Figure 3A and 3B) . We then intercrossed Sema3a Ϫ/Ϫ mice with a Vegfr3::YFP (yellow fluorescent protein) reporter mouse 25 to perform real-time monitoring of lymphatic vessel sprouting in the skin of newborn mice. Fluorescent images taken every 24 hours in the same pups showed that both wild-type and Sema3a Ϫ/Ϫ mice developed lymphatic sprouts that progressively covered the skin in the vicinity of the eyelid and that their overall length and number of branch points was similar in both genotypes ( Figure 3C through 3F) . These results show that lymphatic sprouting Sema3a Ϫ/Ϫ mice proceeds normally.
To investigate blood vascular patterning, we stained the skin of neonatal Sema3a Ϫ/Ϫ mutants and their littermates with the pan-endothelial marker CD31. Vascular develop- arrows, F) . G, HDLEC protein extracts subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blots were incubated with the indicated antibodies. HDLEC express Nrp1, PlexinA1, and Sema3A. H, HDLEC were serum-starved and stimulated with Sema3A for 15 minutes. Nrp1 was immunoprecipitated from cultures, and Western blots were probed with indicated antibodies. Quantification of 3 independent experiments shows that Sema3A treatment enhances Nrp1/PlexinA1 complex formation. Bars represent SEM. *PϽ0.05 (t test). Scale bars: 50 m. ment in the skin was similar between both genotypes (Online Figure III) , consistent with previous results on embryonic vascular development in Sema3a Ϫ/Ϫ mutants. 22 Finally, Sema3A is required for the normal fasciculation of peripheral nerve fibers, 26 which produce VEGF-A to induce arterial differentiation in the skin; consequently arteries follow disorganized nerve fibers in Sema3a Ϫ/Ϫ mice. 16, 17 We considered that impaired sensory nerve and arterial patterning in Sema3a Ϫ/Ϫ mice might affect lymphatic vessel assembly and patterning. To address this possibility, we first compared the development of lymphatics, arteries, and sensory nerve fibers using confocal microscopy of whole-mount wild-type skin immunolabeled with specific markers (Figure 4A  through 4D) . We observed an alignment of large, future collecting Nrp2-positive lymphatics 15 with large Connexin40-positive (Cx40) arteries ( Figure 4A and 4B) . In contrast, smaller-diameter lymphatic vessel branches showed no alignment with smaller-diameter arterial branches, indicating that the coalignment of lymphatics and arteries is restricted to the large-vessel segments ( Figure 4A and 4B) . Sensory nerve fibers only aligned with smaller-diameter arterial branches and were neither aligned with the major arteries nor with the lymphatic vessels ( Figure 4B through 4D) .
We next compared the development of collecting lymphatic vessels in Sema3a Ϫ/Ϫ mice and their wild-type littermates intercrossed with the Vegfr3::YFP reporter mouse. 25 We observed that the large collecting lymphatics were positioned normally alongside major Nrp1-expressing arteries and that the patterning of both major arteries and collecting lymphatics was similar in both genotypes ( Figure 4E through 4L). As lymphatic vessel patterning was initially normal in Sema3a Ϫ/Ϫ mice, valve defects seen in these mice at later stages cannot be secondary due to abnormal arterial patterning or branching of peripheral sensory axons. Given the absence of any detectable defects in angiogenesis or lymphatic vessel development besides the abnormal valves, we conclude that Sema3A is selectively required for lymphatic valve morphogenesis, in line with its strong binding to lymphatic valves.
Defective valve morphogenesis is expected to lead to aberrant lymph fluid transport. 7 However, detailed analysis of lymph fluid transport in Sema3a Ϫ/Ϫ , Nrp1 semaϪ/Ϫ , or Plxna1 mutants was impossible because of perinatal lethality of these mice. 20, 23, 27 Fluorescent dextran injection into the forelimb footpad of wild-type mice at postnatal day 6 (P6) showed that fluorescein isothiocyanate (FITC) is taken up by lymphatic capillaries and transferred to the axillary lymph nodes through one major unbranched collecting lymphatic 28 (Online Figure IV) . In contrast, Sema3a Ϫ/Ϫ mice surviving until P6 displayed an increased area of FITC-perfused lymphatic vessels (Online Figure IV) . Rhodamine-dextran into the footpad of P6 Sema3a Ϫ/Ϫ mice carrying a Vegfr3::YFP reporter showed small lymphatic valves located at branch points in the mutant collecting lymphatics that were insufficient to prevent backflow of the lymph into the side branch (Online Figure IV) , suggesting that defective valve formation in Sema3a mutant mice may cause aberrant lymph drainage.
In addition to a reduction in valve size (Figure 2 ), Sema3a Ϫ/Ϫ mice exhibited abnormal SMC coating of the valve regions ( Figure 5A through 5D) . Thus, wild-type mice showed anti-smooth muscle actin (SMA)-positive staining of collecting mesenteric lymphatics, but valve-forming areas were devoid of SMC ( Figure 5A and 5B). In contrast, the valve-forming areas of Sema3a mutant mice exhibited abnormal SMC coating ( Figure  5C and 5D). Injecting neonatal mice with an antibody that blocks Sema3A binding to Nrp1 (anti-Nrp1 A , 29 ) also resulted in abnormal SMC coverage of valve areas ( Figure 5E and 5F), whereas injection of an antibody that blocks VEGF binding to Nrp1 (anti-Nrp1 B ) had no effect on SMC coverage ( Figure 5G and 5H). We quantified the Itg␣9-positive valve area covered by SMA-positive cells and found that it was significantly increased in Sema3a Ϫ/Ϫ and anti-Nrp1 Atreated mesenteries compared with controls ( Figure 5I ). These results suggest that in addition to valve-forming endothelial cells, Sema3A might act on SMC and repel them away from the valve-forming area.
Discussion
The results described here show that Sema3A is required for proper morphogenesis of lymphatic valves. Our study was prompted by the observation that Sema3A is expressed at high levels in adult lymphatic vessels. 4 Transcriptomic profiling of purified lymphatic endothelial cells (LECs) has confirmed that Sema3A expression is highly specific for LECs (M. Detmar, personal communication, 2008). We demonstrate expression of Sema3A mRNA in neonatal lymphatic vessels but not arteries or veins. Moreover, we found that Sema3A protein binds to lymphatic valves and that its receptors Nrp1 and PlexinA1 are strongly expressed by valve cells.
In line with its preferential binding to valves, our data show that Sema3A plays a selective role in lymphatic valve formation and that other aspects of vascular and lymphatic development including angiogenesis, lymphatic sprouting, and assembly proceed normally in the absence of Sema3A. We confirm previous reports of abnormal sensory nerve and arterial patterning in Sema3a mutants 17 and show that these defects do not affect lymphatic sprouting or assembly. Our data also confirm previous studies showing that Sema3A function is not required for developmental angiogenesis 22 except in certain vascular beds such as the kidney. 24, 30 In contrast to developing vessels, systemic and targeted delivery of Sema3A has been shown to inhibit tumor angiogenesis, 31, 32 indicating that Sema3A signaling is context dependent and regulated differently in developing and tumor vessels.
Nrp1 has previously been shown to be a direct Foxc2 target. 8 It is thus likely that Foxc2 activation leads to specification of future valve cells in the lymphatic wall and concomitant upregulation of Nrp1 expression in these cells. Our analysis of Sema3a Ϫ/Ϫ , Nrp1 sema3aϪ/Ϫ , and Plxna1 Ϫ/Ϫ mice shows that Foxc2 and Itg␣9 are expressed in mutant valve cells. These results suggest that valve cell become properly specified in the mutants and indicate that Sema3A-Nrp1 signaling functions downstream of the valve specification program to direct proper valve morphogenesis.
Our data support a dual role for Sema3A signaling in lymphatic valve formation. One possible mode for Sema3A-Nrp1-PlexinA1 signaling is that Sema3A, produced by the LEC wall, acts on Nrp1-PlexinA1-expressing cells in the newly specified valve to regulate their migration, perhaps generating a repulsive signal that "pushes" the valve cells away from the lymphatic wall to enable valve morphogenesis. Accordingly, the absence of Sema3A-Nrp1-PlexinA1 signaling leads smaller mesenteric valves (Figure 2) , perhaps due to defective migration of valve-forming cells. Analysis of endothelial-specific Nrp1 mutants will confirm if reduced valve size is due to lack of Sema3A signaling through Nrp1 in endothelial cells. In addition to their reduced size, valves in Sema3a mutants and in mice treated with an antibody blocking Sema3A binding to Nrp1 show increased SMC coverage ( Figure 5 ), suggesting that Sema3A may repel SMC away from lymphatic valves. This could occur directly via receptor expression on SMC or indirectly via molecules secreted from receptor expressing valve cells. Our expression data show that valve cells preferentially produce Nrp1 and PlexinA1 mRNA and that Sema3A-AP strongly binds to valves. However, we cannot exclude that SMC sur- rounding lymphatics may express lower levels of Sema3A receptors, and arterial SMC lining the lymphatics express Nrp1. 33 Cultured vascular SMC express Sema3A, Nrp1, and PlexinA1 protein, and Sema3A and PlexinA1 can be coimmunoprecipitated with an antibody against Nrp1 in SMC and in HDLEC (Figure 1 and data not shown) . SMC-specific deletion of Nrp1 will be required to determine if Sema3A signals through Nrp1 in SMC to repel them away from valve-forming areas.
Abnormal SMC coverage of lymphatic valves and loss of valve leaflets are also seen in mouse mutants for the transcription factor Foxc2 8,10,11 and contribute to lymphedema distichiasis in human patients with Foxc2 mutations, 12 highlighting the importance of coordinated extension of valve leaflet endothelial cells and repulsion of SMC from the lymph vessel wall. Future studies will determine if lack of Sema3A signaling in mice and in human patients may contribute to lymphedema formation. Surprisingly, despite its prominent expression in the lymphatic system, Nrp2 expression is excluded from lymphatic valves, and Nrp2-deficient mice show no defects in lymphatic valve formation. Lymphatic sprouts strongly express the Nrp2 receptor, and we have previously shown that LEC sprouting requires VEGF-C binding to a VEGFR3-Nrp2 complex. 19 Site-specific expression of guidance receptors could contribute to specific cell behaviors, and combinations of a repertoire of such receptors could possibly generate a multitude of different cell behaviors. There is precedence for the combinatorial use of neuropilin receptors in the literature. For example, Sema3A exerts a repulsive response on the axons of the facial motor nerve via Nrp1. 26 At the same time, Nrp1 is also expressed on the cell bodies of these neurons and binds VEGF, which guides their movement and is required for proper localization of the cell bodies within the hindbrain. 34 The same cell can therefore use different Nrp1 ligands to regulate movement at its front and rear end. Similarly, association of PlexinD1 with VEGFR2 regulates fasciculation of one specific axonal tract in the forebrain, whereas PlexinD1 associates with neuropilin receptors in other axonal tracts. 35 Combinatorial association of signaling modules, including binding and signal-transducing receptors, may be required to generate diverse cell behaviors in the vascular and nervous systems from a limited number of components. Strikingly, Sema3A in the lymphatic system plays a dual role-to regulate valve forma- 
